2013 Annual Meeting | Case Studies: Neurologic Consultations in Cancer Patients

Date Thursday 03/21/13

Time 06:00 PM - 09:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Extended Seminar

Director(s) David Schiff, MD, FAAN

Topic(s)

Learning Objectives Participants should be able to: provide optimal supportive care for patients with brain tumors regarding seizures, venous thromboembolism, and vasogenic edema; recognize CNS infections in patients with cancer and plan appropriate diagnostic evaluations; determine when neuropathy is likely attributable to chemotherapy, when further studies are indicated, and address therapy and prognosis; diagnose neoplastic meningitis, determine as part of an interdisciplinary team which patients may benefit from therapy, and select the optimum therapy in such cases; and understand the diagnosis and management of neurocognitive issues (including 'chemo-brain') in brain tumor patients.

CME Available No CME available

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
06:00 PM - 06:25 PM		Seizures in Brain Tumor Patients: When and How to Treat? Amy A. Pruitt, MD, FAAN
06:25 PM - 06:50 PM		Avastin®: Benefits and Risks in Neuro-oncology Patrick Y. Wen, MD, FAAN
06:50 PM - 07:10 PM		Brain Tumors and Anticoagulation: When Are These Compatible? David Schiff, MD, FAAN
07:10 PM - 07:35 PM		Does This Patient Receiving Cancer Therapy Have a CNS Infection? Amy A. Pruitt, MD, FAAN
07:35 PM - 07:50 PM		Break
07:50 PM - 08:15 PM		Chemotherapy-induced Neuropathy: Evaluation, Management, and Prognosis David Schiff, MD, FAAN
08:15 PM - 08:40 PM		Leptomeningeal Metastasis: When Is Treatment Likely to Help? Patrick Y. Wen, MD, FAAN
08:40 PM - 09:00 PM		Diagnosis and Management of Neurocognitive Issues in Brain Tumor Patients David Schiff, MD, FAAN

Faculty Disclosures
Amy A. Pruitt, MD, FAAN	Dr. Pruitt has nothing to disclose.
Patrick Y. Wen, MD, FAAN	Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Black Diamond . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celularity. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chimerix. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Day One Bio . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genenta. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Glaxo Smith Kline . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mundipharma. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nuvation Bio . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prelude Therapeutics . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sagimet. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sapience. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vascular Biogenics . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for VBI Vaccines . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zeneca . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Black Diamond . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celularity. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chimerix. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Day One Bio . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genenta. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Glaxo Smith Kline . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mundipharma. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nuvation Bio. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novocure. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prelude Therapeutics. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sagimet. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sapience. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier. Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vascular Biogenics . Dr. Wen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for VBI Vaccines . Dr. Wen has received research support from Astra Zeneca . Dr. Wen has received research support from Black Diamond . Dr. Wen has received research support from Bristol Meyers Squibb . Dr. Wen has received research support from Celgene. Dr. Wen has received research support from Chimerix. Dr. Wen has received research support from Eli Lily . Dr. Wen has received research support from Erasca. Dr. Wen has received research support from Genentech/Roche . Dr. Wen has received research support from Kazia . Dr. Wen has received research support from MediciNova. Dr. Wen has received research support from Merck. Dr. Wen has received research support from Novartis. Dr. Wen has received research support from Nuvation Bio . Dr. Wen has received research support from Servier. Dr. Wen has received research support from Vascular Biogenics . Dr. Wen has received research support from VBI Vaccines . Dr. Wen has received publishing royalties from a publication relating to health care.
David Schiff, MD, FAAN	Dr. Schiff has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Orbus Pharmaceutical. Dr. Schiff has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��